North America
Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers
First-of-its kind tool to guide HCPs on what to consider when staging patients with Mycosis Fungoides and Sézary Syndrome
Princeton, N.J., April 19, 2025 – Kyowa Kirin, Inc. a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced the launch of a new tool to help healthcare providers (HCPs) navigate the complicated process of accurately staging patients with Mycosis Fungoides (MF) or Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma (CTCL). The tool is now live on PROBEinCTCL.com alongside comprehensive information and resources about CTCL.
“CTCL is a rare form of blood cancer that first appears on the skin, presenting acute challenges in its diagnosis. In fact, many patients go 2 -7 years before receiving an accurate diagnosis,” says Dr. Pamela Allen, MD, a board-certified hematologist. Dr. Allen is one of several physicians who consulted with Kyowa Kirin on the tool’s development. “While clinical jud
19 August 2025
